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Tablet Splitting: “To Split or Not To Split” 
 
Tablet splitting can save patients money, especially when considering sole-source brand name 
products.  Yet, the practice of tablet splitting can be problematic as a result of failed therapeutic 
outcomes due to over or under dosing.  Also, the stability of a medication might be altered or there 
may be other unknown reasons not to split a tablet.  The following checklist and guide may help 
you determine which patients are able to split their own tablets and which tablets might safely be 
split.5   
 
A. Patient Considerations: 
a. Physical ability: 
i. Does the patient or patient’s caregiver have the skill, dexterity, strength, and 
visual ability to split a tablet?   
 No, splitting should not be considered 
 Yes, go to the next question  
b. Cognitive ability: 
i. Does the patient or patient’s caregiver have the mental ability to select the 
correct medication and split a tablet?   
 No, splitting should not be considered 
 Yes, go to the next question  
 
B. Product Considerations (Drug, Potency, and Dosage Form): 
a. Is the active ingredient a narrow therapeutic index product (digoxin, levothyroxine, 
others)? 
 Yes, splitting should not be considered 
 No, go to the next question  
b. Is the tablet a controlled- or modified-release product? 
 Yes, go to the next question 
1. Is the tablet scored? 
 No, splitting should not be considered 
 Yes, go to the next question  
 No, go to the next question  
c. Does the tablet contain more than one active ingredient? 
 Yes, splitting should not be considered 
 No, go to the next question  
d. Does the tablet easily break into pieces with minimal handling (friability)? 
 Yes, splitting should not be considered 
 No, go to the next question  
e. Is the tablet enteric-coated, sublingual, or buccal  
or 
does it have a poor taste, is it teratogenic if handled, or can it cause mouth irritation? 
(See Detail-Document # 241204 “Medications That Should Not be Crushed” for 
a helpful list of these medications). 
 Yes, splitting should not be considered 
 No, splitting is possible.  
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Tablet Splitting: “To Split or Not To Split” 
 
Background 
Tablet splitting has been a popular, cost-saving 
practice among many patients for years.  Patients 
have been able to trim prescription costs by 
splitting a tablet in halves or quarters.  This is 
achievable because the prices of some drugs are 
similar despite the strength of the tablet.  Now, 
some HMOs and insurance companies are 
utilizing tablet splitting as a cost-saving strategy.  
They are implementing policies that often require 
patients to split tablets of some commonly used 
medications.1,2  A December 2000 class-action 
lawsuit in the California court system contends 
that Kaiser Permanente has required its health 
plan members to split tablets regardless of the 
patients’ ability to accurately split tablets and the 
products’ suitability for splitting.  The lawsuit 
states that Kaiser’s tablet-splitting policy is a 
violation of the California Business and 
Professions Code and the state’s Consumer Legal 
Remedies Act.3  National pharmacy and medical 
societies have expressed several concerns over 
this controversial issue.  Primary concerns have 
ranged from the patient’s ability to accurately split 
the tablet, the content uniformity of the split 
tablet, and the possibility of a prescription error if 
“1/2 tablet” is misinterpreted as “1-2 tablets.”4-7 
 
Views of Professional Organizations 
The American Pharmacists Association and the 
American Medical Association are both formally 
against mandatory tablet splitting.5  The American 
Pharmacists Association (APhA) acknowledges 
the widespread practice of tablet splitting, and has 
developed a set of guidelines to evaluate the 
appropriateness of tablet splitting based on 
individual patient and product characteristics.  
The APhA suggests tablets that are uncoated and 
scored, for example, are often the easiest to split.  
Tablets that are round, coated, small, or unscored 
may be difficult to split accurately.  The patient or 
caregiver must also be physically able to divide 
the tablet as directed.5-7  The American Society of 
Consultant Pharmacists opposes policies that deny 
payment for lower strengths of tablet dosage 
forms, or policies that mandate tablet splitting by 
patients.4  The Department of Veterans Affairs 
(VA) has also investigated this issue.  Although 
the VA did not find specific studies indicating 
tablet splitting was detrimental to patients, the VA 
does not currently recommend mandatory tablet 
splitting.8 
 
Studies 
Rosenberg et al evaluated the weight-
variability of twenty-two prescriptions containing 
560 pharmacist-dispensed split tablet halves.  The 
United States Pharmacopeia (USP) tablet 
uniformity standards require tablets to contain 
between 85% and 115% of the labeled dosage, 
allowing a 6% relative standard deviation in 
overall drug content.  Of the twenty-two 
prescriptions tested, only seven (31.8%) met USP 
tablet uniformity standards.  In addition, five of 
the twenty-two products had more than 10% of 
their fragments beyond this range.9   
In another study, Teng et al evaluated the 
accuracy of tablet splitting by a trained individual.  
In this study, tablets found to be commonly 
divided were split by hand alone and by a single-
edged razor blade.  The trained individual split 
tablets of three products by hand, and tablets of 
eleven products with a single-edged razor blade.  
The three hand-split tablet groups and eight of the 
eleven groups split with a single-edged razor 
blade failed to meet USP tablet uniformity 
standards.10  
Polli, et al examined the issue of tablet 
splitting within the Veterans Affairs (VA) 
Maryland Healthcare System.  In 2001, this 
regional VA system promoted tablet splitting of 
products including atorvastatin, citalopram, 
lovastatin, paroxetine, sertraline, sildenafil, and 
simvastatin.  Patients, however, could opt out of 
the program if they had difficulty splitting the 
tablets.  The study examined the accuracy of 
twelve commonly split tablets.  A trained 
pharmacy student split 30 tablets of each product 
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using a splitter device provided by the VA, and 
the tablet halves were then assessed for weight 
uniformity.  Eight of the twelve products (67%) 
tested passed the USP-based uniformity testing, 
while four failed.11   
A separate retrospective study by Gee, et al 
evaluated the effects of splitting HMG-CoA 
reductase inhibitors.  A total of 2,019 patients 
were enrolled and evaluated on parameters such 
as clinical effects, patient satisfaction, 
compliance, and cost issues.  The cost avoidance 
over a one-year period for splitting atorvastatin, 
lovastatin, and simvastatin was estimated to be 
$138,108, an average of $68.40 per patient per 
year.  Of the 454 patients who filled out the 
satisfaction questionnaires, 46% believed it was 
easier to take medications they did not have to 
split.  However, 74% believed the tablet splitter 
was not too bothersome or time-consuming.  
Another 7% believed they had missed more doses 
during a month of tablet splitting.  Of the 512 
patients evaluated for laboratory considerations, 
there was no difference in total cholesterol and 
triglyceride values before or after tablet splitting 
was initiated.  Statistically significant differences 
did show for AST (26 versus 28, p<0.001), ALT 
(24 versus 28, p=0.006), LDL (102 versus 97, 
p<0.001), and HDL (46 versus 48, p<0.001) after 
the introduction of the tablet splitting process.  It 
should be noted that the baseline lab panel test 
results recorded in the study could range from one 
year before to the day of tablet splitting initiation.  
Once tablet splitting began, a lab panel could be 
obtained between six weeks and one year while in 
the splitting phase of the study.12 
 
Conclusion 
Mandatory tablet splitting remains a 
controversial policy.  Because of the variability in 
dose that may occur with tablet splitting, this 
practice should probably be avoided when 
accuracy of the dose is crucial.  Enteric-coated 
and certain controlled-release tablets are not 
intended for splitting.  It might be prudent to 
contact the tablet manufacturer before 
recommending tablet splitting, when in doubt.  
The stability of the medication might be altered or 
there may be other unknown reasons not to split a 
tablet.  The patient’s individual ability to 
accurately split the tablet and the medication itself 
should continue to be key concerns.     
 
Users of this document are cautioned to use their own 
professional judgment and consult any other necessary 
or appropriate sources prior to making clinical 
judgments based on the content of this document.  Our 
editors have researched the information with input 
from experts, government agencies, and national 
organizations.  Information and Internet links in this 
article were current as of the date of publication. 
 
Project Leaders in preparation of this Detail-
Document:  Jennifer Obenrader, Pharm.D. and 
Joseph A. Woelfel, Ph.D., FASCP, R.Ph., 
Assistant Editor 
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